Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017
- GDHC4403CTIDB
- Pages: 166
- July 2017
- Total Views:1177
- Region : Global
- GlobalData
- Market Research Report
Details
Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017
Summary
GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017" provides an overview of Duchenne Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials 35
Prominent Drugs 37
Latest Clinical Trials News on Duchenne Muscular Dystrophy 38
Jul 18, 2017: PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet 38
Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy 38
Jun 23, 2017: Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent at the 2017 PPMD Annual Connect Conference 39
Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress 39
Jun 22, 2017: New Analyses of Translarna (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress 39
Jun 14, 2017: CureDuchenne to Host Webinar with Santhera Pharmaceuticals on SIDEROS Trial 40
May 30, 2017: Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF- 06252616) in Duchenne Muscular Dystrophy 40
May 23, 2017: New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting 40
May 16, 2017: Santhera to Present Data and Host Symposium on Pulmonary Function in Duchenne Muscular Dystrophy at the American Thoracic Society 113th Annual Conference 40
May 15, 2017: Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD 41
May 11, 2017: New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy 42
May 03, 2017: GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics 42
Clinical Trial Profile Snapshots 43
Appendix 164
Abbreviations 164
Definitions 164
Research Methodology 165
Secondary Research 165
About GlobalData 166
Contact Us 166
Source 166
List Of Figure
List of Figures
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 16
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 17
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 22
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37
GlobalData Methodology 165
List Of Table
List of Tables
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2017* 8
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 16
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 18
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 23
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2017* 26
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Duchenne Muscular Dystrophy Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Duchenne Muscular Dystrophy, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
BioMarin Pharmaceutical Inc
PTC Therapeutics Inc
Sarepta Therapeutics Inc
Marathon Pharmaceuticals LLC
GlaxoSmithKline Plc
Summit Therapeutics Plc
Akashi Therapeutics Inc
Prosensa Holding B.V.
CureDuchenne
Catabasis Pharmaceuticals Inc
Company Profile
Company Profile Title
Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017
Summary
GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017" provides an overview of Duchenne Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials 35
Prominent Drugs 37
Latest Clinical Trials News on Duchenne Muscular Dystrophy 38
Jul 18, 2017: PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet 38
Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy 38
Jun 23, 2017: Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent at the 2017 PPMD Annual Connect Conference 39
Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress 39
Jun 22, 2017: New Analyses of Translarna (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress 39
Jun 14, 2017: CureDuchenne to Host Webinar with Santhera Pharmaceuticals on SIDEROS Trial 40
May 30, 2017: Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF- 06252616) in Duchenne Muscular Dystrophy 40
May 23, 2017: New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting 40
May 16, 2017: Santhera to Present Data and Host Symposium on Pulmonary Function in Duchenne Muscular Dystrophy at the American Thoracic Society 113th Annual Conference 40
May 15, 2017: Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD 41
May 11, 2017: New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy 42
May 03, 2017: GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics 42
Clinical Trial Profile Snapshots 43
Appendix 164
Abbreviations 164
Definitions 164
Research Methodology 165
Secondary Research 165
About GlobalData 166
Contact Us 166
Source 166
List Of Figure
List of Figures
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 16
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 17
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 22
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37
GlobalData Methodology 165
List Of Table
List of Tables
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2017* 8
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 16
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 18
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 23
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2017* 26
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Duchenne Muscular Dystrophy Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Duchenne Muscular Dystrophy, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
BioMarin Pharmaceutical Inc
PTC Therapeutics Inc
Sarepta Therapeutics Inc
Marathon Pharmaceuticals LLC
GlaxoSmithKline Plc
Summit Therapeutics Plc
Akashi Therapeutics Inc
Prosensa Holding B.V.
CureDuchenne
Catabasis Pharmaceuticals Inc
: +91 9015378249
Related Reports
Page 157 | 
June 2021
Page 130 | December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020